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Sustainable economic growth requires innovation
and adequate human capital and employment
In the 2030 Agenda for Sustainable Development (see
e.g. United Nations, 2015a,b), which places people, pla-
net, prosperity, peace and partnership at the centre of
an action plan encapsulated in the Sustainable Develop-
ment Goals, economic growth, enterprise creation and
employment opportunities represent a key building block
that is articulated in SDG 8: Promote sustained, inclusive
and sustainable economic growth, full and productive
employment and decent work for all.
Traditional primary and secondary business sectors
have contributed signiﬁcantly to economic growth in par-
ticular in high- and middle-income countries; however,
these sectors are primarily based on redistribution/trans-
formation, i.e. mining, harvesting, reﬁning, processing,
utilizing and disposing of ﬁnite (e.g. ore, oil) or tempo-
rally limited (e.g. crops) resources. Even a purely anthro-
pocentric view of the planet is constrained by the fact
that it and its inhabitants are subject to basic ecological
rules (the food/energy pyramid, functional changes in the
planetary ecological network induce compensatory reac-
tions elsewhere in the network, etc.), ﬁnite resources
and ecological consequences of environmental abuse.
Thus, the notion that perpetual economic growth of tradi-
tional business sectors is possible and sustainable is
unrealistic. The central task is thus to focus strategic
economic development investment in new business
growth sectors that most effectively and sustainably inter
alia increase productivity, streamline consumption and
scale down waste, in order to create a healthy economic
growth trajectory within the global context. This will
necessitate implementation of strategic policies designed
to drive development of innovative solutions, which efﬁ-
ciently maximize the utility of local and regional advan-
tages, incentivize diversiﬁcation, establish centres of
excellence, foster transnational public and private part-
nerships, attract investment, etc., to sustainably increase
domestic and international value and, in turn, grow
economies. Here we (i) argue that biotechnology and, in
particular, microbial biotechnology offer huge potential to
sustainably drive enterprise, employment and expertise
creation and (ii) provide some examples of challenges
and solutions, that may guide policy makers in the for-
mulation and implementation of relevant policies that will
facilitate economic growth.
Population growth, demographic transition and the
demographic dividend
Without doubt, one major factor requiring particular con-
sideration in sustainable development strategies is the
rate at which the global community has been growing
and is projected to grow in the foreseeable future. The
dramatic growth rates witnessed since the middle of the
20th century, most prominently in developing regions,
are inter alia due to signiﬁcantly improved public health
measures, in particular measures to prevent infectious
diseases and reduce malnutrition, which predominantly
affect children. Such measures have achieved substan-
tial reductions in infant mortality and increases in life
expectancy, improved overall health and resulted in
important shifts in age distributions in low- and middle-
income countries (lower average ages): the demographic
transition. As the risk of infant mortality declines, parents
tend to have fewer children; as urbanization, vocational
prospects and salaries increase, the demand for a more
highly skilled workforce grows, and the relative beneﬁt of
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basic skills, such as farming, declines; as, in turn,
employment prospects and return on investment in
higher skills improve, parents tend to invest more in the
education of their offspring to improve their chances in
the labour market. This leads to successive generations
of increasingly highly trained individuals which, over
time, substantially increase the proportion of economi-
cally active individuals in a population and, in turn, signif-
icantly improve the potential for economic growth and
development: the demographic dividend. However,
exploitation of this economic growth potential is highly
dependent on utilization of a window of opportunity (circa
one century) and, importantly, a favourable and respon-
sive policy environment, principally regarding the ade-
quate support of the new labour supply and the
increases in savings and human capital (see e.g. Bloom
et al., 2003; Bloom, 2015).
Maximizing the potential of this new labour supply,
and thereby exploiting the momentum to grow the econ-
omy, requires policies that focus on sustainably ensur-
ing adequate job opportunities for the growing and
increasingly skilled workforce. Due to increased produc-
tivity and hence earnings by public and private organi-
zations, and individual households, capital savings
(pensions, tax revenues, private equity, etc.) become
available. Policies need to adequately regulate and
increase trust in capital markets, and incentivize
national and international trade, and, importantly, diver-
siﬁed individual and aggregate domestic (and foreign
direct) investment, in particular in growth sectors and
research and development. Improvements in education
and health, which are mutually re-enforcing and offer
substantial return on investment for individuals and soci-
ety as a whole, are central for economic growth. There-
fore, policies should focus on creating and appropriately
fostering an environment to sustainably increase social
and human capital with a view to consolidating current,
and paving the way for improved, economic growth tra-
jectories (see e.g. Bloom et al., 2003; McTaggart et al.,
2012). In addition, during transition from low- to middle-
to high-income settings, policy makers must be aware
of and responsive to the changing determinants of eco-
nomic growth pertinent to their setting (e.g. workforce
specialization) and adapt policies accordingly to most
effectively sustain growth momentum and avoid produc-
tivity stagnation, sometimes also referred to as the ‘low-
growth trap’ (see e.g. Agenor and Canuto, 2015;
Bulman et al., 2017; Engel and Taglioni, 2017).
The bio-based economy – facilitating current and
future economic growth
As alluded to above, the creation of new employment
opportunities is dependent on a number of parameters,
such as demand, capital expenditure, distribution of the
rents of productivity growth (UNCTAD, 2012), but bal-
anced growth of existing commercial enterprises, for
example through establishment of interconnected (spe-
cialized) local/regional R&D hubs (see e.g. Frost and
Sullivan, 2011; Damond, 2014), and, importantly, the
creation of innovative new businesses, are fundamental.
Numerous individuals and organizations have empha-
sized the economic potential of knowledge-based busi-
ness sectors, and the need to invest in and nurture
them, and in the infrastructure needed for them to thrive.
The bio-based economy is one of the key sectors in this
category, able to proﬁt from the accelerating rate of new
discoveries and technical developments. It is also one of
the most investment- and human capital-intensive, fast-
est growing, lucrative and ﬂexible (e.g. scalable) innova-
tion sectors. Globally, the bio-based economy is
projected to grow by at least 50% by 2030 (Bio, 2017).
Whilst addressing local and regional challenges with bio-
tech innovation, the bio-based economy in low- and mid-
dle-income countries can take advantage of the
international pull effects for new solutions and thus
emerging R&D opportunities. Currently, biotechnology is
also one of the key drivers for medical innovation.
Biosimilars, for example, represent one highly relevant
area within the future biotech landscape (IMS Institute
for Healthcare Informatics, 2016), as payer organizations
in many healthcare systems, especially in high-income
countries, are seeking a broader array of, and less costly
and more effective treatment alternatives. Provided ade-
quate regulatory and quality measures are in place, pub-
lic innovation funds are made available, and incentives
for domestic and foreign direct investment are intro-
duced, biotechnology will be an ideal and synergetic dri-
ver of the demographic dividend in a variety of settings,
by offering opportunities to a growing and more highly
skilled workforce, and increasing investment opportuni-
ties and human capital. It is ideally suited not only for
R&D of new and more efﬁcient products, processes and
services, but also for diversiﬁcation, that increase pro-
ductivity and scale down waste: less space, less matter,
less waste, for more.
Microbial biotechnology – exceptional diversity of
applications and opportunities for specialization
Microbial biotechnology is both one of the oldest tech-
nologies (fermentation history is as old as civilization)
and one of the newest and most rapidly growing indus-
tries (the highest number of start-ups, globally, are
microbiome-based biotechnology companies). The ﬁeld
has thus a long pedigree of experience and experimen-
tation and is currently enjoying an exceptionally exciting
period of continuous discoveries.
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Applications that resulted from or are now emerging
out of advances in microbial biotechnology research are
manifold and exceptionally diverse and include: diagnos-
tics, pharmaceuticals, immune prophylactics, microbial
therapies, fermented foods, food supplements, plant
growth promotion and protection agents, biocatalysis
and green chemistry, chemical feedstocks, biopolymers
and biomaterials, biosurfactants and emulsiﬁers, compat-
ible solutes and bioprotectants, fermentation, bioenergy
from renewable feedstocks, fossil fuel recovery and val-
orization, bioelectricity, clean water provision, recycling
technologies, wastewater treatment, bioremediation, bio-
mining, metal and nutrient recovery, carbon capture,
self-healing concrete, protection of cultural goods. The
diversity of applications is on the same scale as that
enjoyed by chemistry and chemicals. And, importantly,
the range of diversity of applications is expanding
weekly, witness the explosion of new applications in the
ﬁeld of microbiome technology. This means that the
range of possibilities for specialization and niche prod-
ucts from microbial biotechnology is exceptionally wide
and can thus aliment many large, medium and small
enterprises with proﬁtable business opportunities (see
also SDG 8.2 Achieve higher levels of economic produc-
tivity through diversiﬁcation, technological upgrading and
innovation, including through a focus on high-value
added and labour-intensive sectors; see e.g. United
Nations, 2015a,b).
Microbial biotechnology – exceptional innovation and
entrepreneurial actors
Application diversity potential does not, of course, auto-
matically translate into commercial activities, business
expansion or growth in employment: the potential has to
be mined, concretized, developed, reﬁned and marketed,
all of which require talented innovators working in a
favourable environment. Innovation and entrepreneurial
approaches are key in unlocking new products, pro-
cesses and services, gaining market access, and suc-
cessful commercialisation.
There are a number of parameters that can be taken into
consideration for assessing the innovation level of a partic-
ular sector, including the annual number of patent applica-
tions/research papers published/scientiﬁc meetings, the
rate of creation of new dedicated university departments,
Fig. 1. Growing the bioeconomy and increasing the demographic dividend to enhance economic development – illustration in part based on
Bloom, Canning et al., 2003; McTaggart, Findlay et al., 2012.
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rate of creation of start-ups, and by all these parameters,
biotechnology is seen to be highly innovative. For a current
snapshot of innovations in diverse sectors of microbial
biotechnology, the reader is directed to the contributions
published in this issue, particularly those by (Alvarez and
Fernandez, 2017; Caselli, 2017; Cordero et al., 2017;
D€urre, 2017; Felgner et al., 2017; Garcia, 2017; Godoy
et al., 2017; Gurry, 2017; Lee, 2017; Li and Gadd, 2017;
de Lorenzo, 2017; Macaskie and Orozco, 2017; Narancic
and O’Connor, 2017; Nealson, 2017; Ramos, 2017; Sch-
midt-Dannert, 2017; Sherry et al., 2017; Trivedi et al.,
2017; Verstraete and Devrieze, 2017; Webster, 2017) –
see also SDG 8.3 Promote development-oriented policies
that support productive activities, decent job creation,
entrepreneurship, creativity and innovation, and encourage
the formalization and growth of micro-, small- and medium-
sized enterprises, including through access to ﬁnancial ser-
vices (see e.g. United Nations, 2015a,b).
Need to nurture innovation
While the long-term success of an organization is deter-
mined by a number of indicators, originality and innovation
are undoubtedly paramount, both for its successful evolu-
tion and for funder/customer perception of its quality and
potential. Innovation itself is inﬂuenced by a number of
factors, particularly the availability, density and diversity of
innovators, newest information and ideas, the prevailing
degree of ‘innovation culture’ and the inﬂuence of innova-
tion facilitators, such as administrators and managers –
gatekeepers – who decide on the further development of
discoveries/advances. Innovation is often taken for
granted/discussed as though it were a commodity – a
parameter among many to be managed – but true innova-
tors, like the best artists, surgeons, violinists, managers,
politicians, are a rare species and require explicit support,
which is frequently a necessary degree of ‘guided’ free-
dom, in order to ﬂourish. Productive, synergistic innova-
tor:gatekeeper partnerships are crucial, so gatekeepers
need to be involved at an early stage in development of
innovative ideas in order to provide the support needed for
further development and commercialization.
Sustainability considerations will shift perception of
application value
While many biotechnology products and processes are
inherently high value, others (particularly those that
improve the quality of degraded environments, such as
bioremediation and biomining) tend to be perceived as
low value, often uncompetitive with existing feedstocks
and technologies (frequently due to an unfavourable regu-
latory framework), and hence less attractive for develop-
ment and investment. However, the recognition of the
beneﬁts of such products and processes, and hence their
competitiveness, is fundamentally changing with integra-
tion of sustainability principles into economic analyses,
their consideration not as stand-alone but rather as com-
ponents in cyclical processes and as participating ele-
ments in global issues (e.g. carbon footprints, energy vs.
food, travel/food distribution and disease transmission
control, food costs/food security/producer poverty, energy
sourcing/energy security/political independence, land use
and biodiversity; see the SDG texts in United Nations,
2015a,b), and resulting changes in the regulatory land-
scape. Thus, some currently low value and/or poorly com-
petitive microbial technologies will in the future gain
importance and attract investment as a result of changing
perceptions, policies, regulatory frameworks and increas-
ing beneﬁt.
The increasing importance of artiﬁcial intelligence for
biotechnology – shifting specialization focus
For some time now, there has been a continual acceler-
ation in the speed of data collection and the volumes
collected (in the biotechnology sphere e.g. via next-gen-
eration sequencing, high-throughput assays). Artiﬁcial
intelligence1 (AI) will become the primary means of han-
dling and analysing these vast amounts of data, and
thus a major driver of new discoveries across diverse
scientiﬁc disciplines and industries. AI’s continuously
evolving sophistication, and thus ability to rapidly detect
and ‘learn’ from patterns in vast data sets (numeric
parameters, images, videos, etc., and, if appropriately
equipped with sensory hardware, observe, probe and
examine living beings and other phenomena), will revolu-
tionize the efﬁciency, i.e. speed, accuracy and breadth,
of data analysis. AI will be able to identify or predict pre-
viously unknown relationships of correlation, correlation
direction, causality, etc. (see e.g. Shanahan, 2015), and
costs for input, pattern detection and prediction tasks will
drop signiﬁcantly. It has therefore been suggested that
the current modus operandi of research and develop-
ment in public and private organizations will change dra-
matically. Roles for employees affected by these
changes will increasingly shift towards appraisal and
judgement of the patterns, predictions and inferences
suggested by generic and specialized AI (Agrawal et al.,
2016). A central function for these new roles of judge-
ment will be to adequately investigate and understand
the rationale (criteria, parameters, attributes, etc., i.e.
data sets) according to which AIs have evolved and in
1We use artiﬁcial intelligence here as an umbrella term for the broad
ﬁeld of ‘self-learning’ algorithms and applications, such as super-
vised and unsupervised machine-learning, convolutional neural net-
works.
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which direction the AIs have become increasingly
biased2 (their heuristics, hypotheses formulation, etc.), in
order to judge the validity of AI-based ﬁndings (see e.g.
House of Commons Science and Technology Commit-
tee, 2016; Ingle et al., 2016; Witten et al., 2016; Bughin
et al., 2017). Microbial biotechnology exploits big data in
most of its diverse branches, so it will be a major beneﬁ-
ciary of AI-driven acceleration of data mining, prediction
and discovery. This means that AI will drive the creation
of new enterprises and employment opportunities in the
microbial biotechnology arena, but also changes in the
roles of existing enterprises and employees. The sus-
tainable and adequate exploitation of AI, including the
proper scrutiny of AI-ﬁndings according to scientiﬁc best
practice, will necessitate signiﬁcant investment in educa-
tional and collaboration programmes that speciﬁcally
maximize expertise in judging and translating AI-ﬁndings.
This in turn will lead to improved research and develop-
ment practices of microbial biotechnologies across small
and large, public and private organizations.
Investment in microbial biotechnology as a strategic
priority for economic growth
Enhancing bioeconomies and transnational value
creation
Some of the authors of this paper proposed microbial
biotechnology as a priority target for infrastructure invest-
ment for economic revival of Southern European coun-
tries, following the recent economic crisis that particularly
affected these countries (and still does) (Timmis et al.,
2014). The idea was: all of these countries have excellent
education systems and research expertise, but relatively
modestly funded research bases and little and/or frag-
mented biobusiness. They therefore have potent capaci-
ties to develop biobusiness but lack the necessary critical
mass and political support. We argued that investment of
structural funds to create this critical mass and new
research networks would have a greater and more sus-
tainable long-term impact on economic recovery than tra-
ditional infrastructure investments, like highways and
building programmes. While the investment concept for all
countries was the same: building cutting edge research
infrastructure, signiﬁcant expansion of selective research
capacity in regional hubs, creation of national networks for
discovery of new chemicals through prospecting microbial
diversity and the harnessing of cell biology groups for
screening for agonists–antagonists of newly discovered
cellular targets, the application sector of each would be
different to reﬂect their distinct cultures, resources/access
to resources and business/socio-political priorities: e.g.
Spain is strong in systems and synthetic biology, Portugal
has strong cultural links and privileged access to biodiver-
sity of former colonies, Italy is a leader in exploration of
rare extreme deep sea brine lakes, Greece has a long tra-
dition in maritime trade, and so forth. Even without the
obvious distinctions of history, geography and culture, dif-
ferent regions have different microbial strains which con-
stitute unique resources, e.g. for the local development,
production and exploitation of locally derived inoculants
for growth promotion and protection of crop plants in agri-
culture. Thus, each country could specialize in different
biotechnology sectors – medical applications, agriculture,
environment, and so on. SO: all can cooperate, share
experiences and develop synergies one with another,
because they do not need to directly compete in a signiﬁ-
cant manner. Crucially, the concept presented in the arti-
cle proposes the creation of a professional integrated
ﬁnancial, business and infrastructure framework for the
rapid creation of start-ups by young investigators of the
networks that make the new discoveries (Timmis et al.,
2014).
Since the publication of this article, interest in the con-
cept has been expressed from East European and Latin
American countries, which have similar potential. Like
the countries of Southern Europe, a number of countries
in Latin American and Asia have outstanding medical
systems which could serve as a major resource and
crystallization factor for medical biotechnology biobusi-
ness, developing and trialling new medical and nutri-
tional products. Low- and middle-income countries often
have highly valuable biological resources that can be uti-
lized in the development of new biotechnology applica-
tions. They can either develop these resources
themselves, by investing in the necessary education,
training, infrastructure and leadership, or by developing
synergistic, mutually beneﬁcial cooperations of steward-
ship and strategic joint commercial ventures with appro-
priate partners from other settings.
Thus, this proposal to support economic revival and
enterprise and employment creation through investment
in microbial biotechnology has universal applicability,
given the appropriate political mindset and determination.
And the creation of regional activities based on regional
speciﬁcities creates regional stakeholders that encourage
regional efforts and inclusiveness, corporate identity, com-
mercial participation in regional society, including educa-
tion, health, culture, and of course regional partnerships.
Retaining the return on investment in education and
recruiting new talent
A potential problem for countries with underinvestment in
biotech R&D and business is that their aspirations may be
2For a more detailed account of different biases, such as the lan-
guage, search and overﬁtting-avoidance bias, in inter alia machine
learning, see e.g. (Witten et al., 2016).
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frustrated by a brain drain – their best talent migrates and
then fails to return – thereby constituting a displaced edu-
cational investment and a suboptimal use of national
resources. Moreover, those countries to which talent
migrates tend to have their own highly talented workforce,
which is thereby reinforced and, as a consequence, the
national R&D gap between such countries increases even
further. However, in a highly diverse global economy, in
which individual countries specialize in diverse activities in
which they strategically invest to become and remain
leaders in the ﬁeld, highly trained individuals will be incen-
tivized to migrate only temporarily and return to provide a
return on investment. Therefore, selective investment in
higher education and research training – together with
establishment of the relevant specialist biobusiness –
should be considered priorities to create a regional pool of
talent, expertise and innovation that provides long-term
beneﬁts to both the regional and global economy. In any
case, a diverse, highly motivated, talented, experienced
and effectively networked bioeconomy workforce must be
considered to be a key global economic, intellectual and
cultural ‘good’ of our global society.
Attracting young professionals to the most dynamic
sectors of biobusiness
While there are a number of media which inform about
current recruitment for individual open positions, it is also
important to provide more generic information about
expanding business sectors that offer high employment
potential. As an example of this, to encourage young
biotechnology professionals to gravitate to rapidly evolv-
ing business sectors with high recruitment levels, or at
least to be aware of the employment opportunities avail-
able, Microbial Biotechnology is currently publishing a
series of Editorials on the opportunities of enterprise and
employment creation generated by microbial technology.
This series has so far featured Editorials on microbiome
transplant therapy (van der Lelie et al., 2017), micro-
biome-based products for agriculture (Singh, 2017), micro-
biome-based human forensics (Hampton-Marcell et al.,
2017), do-it-yourself technologies as sources of innovation
in microbial biotechnology (de Lorenzo and Schmidt,
2017), bioprospecting unusual environments (Tanner
et al., 2017) and non-antibiotic feed adjuncts for food ani-
mals (Br€ussow, 2017). Others are in the pipeline.
Conclusions
Microbial biotechnology is a key knowledge-based
biobusiness that has applications in almost all aspects
of life and society and will be a major driver of enter-
prise and employment creation in the future, and hence
signiﬁcantly contribute to SDG 8: Promote sustained,
inclusive and sustainable economic growth, full and pro-
ductive employment and decent work for all. Impor-
tantly, microbial biotechnology offers manifold
opportunities for the creation and exploitation of diverse
partnerships providing more than mere commercial ben-
eﬁts. Implementation of top-down measures for fulﬁl-
ment of the SDGs – together with bottom-up growing
societal demands – will foster new areas of biotechno-
logical activity in both developed and developing coun-
tries. Frontline research will thereby reach out to topics
and scientiﬁc territories typically away from the radar of
investors e.g. large-scale CO2 capture, development of
new antibiotics, combatting poverty-associated diseases,
and multi-scale environmental rehabilitation. The drivers
of this expansion will include not just the habitual hyper-
technological actors that have traditionally dominated
the realm of the bio-based economy, but also frugal
technologists able to translate conceptually sophisti-
cated approaches into user-friendly and affordable plat-
forms. This will certainly help not only to democratize
the functioning of the biotechnological market, but also
enable ideally all countries and communities to access
the type of sustainable prosperity that only modern bio-
sciences, and in particular microbial biotechnology, can
achieve.
However, realization of the potential of microbial
biotechnology to facilitate attainment of SDG 8 needs
support from policy makers, business and educators
who need to recognize that its fundamental strengths –
high innovation, local and regional innovation potential
and diversity of applications – must be fostered/sup-
ported by both investment and gatekeepers. Key factors
to maximize the utility of microbial technology are:
(i) Exploit local and historical strengths and resources
(e.g. Brazil and bioethanol) to increase global diversi-
ﬁcation and specialization, and facilitate the formation
and maintenance of strategic collaborations and part-
nerships, provide an environment (higher education,
research) in which strategic research and know-how
become and remain among the best in the world, and
innovation thrives, and ensure key groups stay at the
cutting edge in selected strategic ﬁelds.
(ii) Establish and ﬁnance strong strategic links between
academia and industry to accelerate commercializa-
tion; facilitate start-ups, acquire and support missing
skills, infrastructure and involve gatekeepers as early
as possible in the process of innovation so that they
can more effectively support progress.
(iii) Establish a policy, regulatory and economic environ-
ment favourable to bioeconomy development and
success. Make innovation a key strategic component
of infrastructure investment and enact policies that
favour and support entrepreneurs.
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(iv) In more general terms, when considering investment
options to increase/facilitate economic growth,
always identify and quantify the rate limiting parame-
ter and then decide which option would best alleviate
it (will this new construction project bring signiﬁcant
beneﬁts over a 5-year/10-year/20-year time span? If
so, how does the calculated beneﬁt compare with that
of investment in an innovation sector?).
Microbial biotechnology is signiﬁcantly contributing, and
has exceptional potential to contribute much more, in
diverse arenas, directly to 10 of the 17 SDGs, one of which,
SDG 8, is the subject of this article, and the others of which
are discussed in this issue. Moreover, progress towards
SDG 8 will also necessarily impact positively on other
SDGs, in particular SDGs 13 and 10,4 but also 4,5 in as
much as embracing and promoting high-tech, innovative
biobusiness necessarily requires high levels of education
for a growing workforce, SDG 5,6 as full employment is inter
alia facilitated by and re-inforces gender equality and
empowerment, and SDGs 167 and 17,8 in so far as high-
tech industries need highly educated work forces which
usually engender societies favouring peace, inclusiveness
and sustainability. Thus, microbial biotechnology con-
tributes/will contribute, directly or indirectly, to almost all of
the SDGs.
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